Improving Drug Delivery for Alzheimer’s Disease Through Nose-to-Brain Delivery Using Nanoemulsions, Nanostructured Lipid Carriers (NLC) and in situ Hydrogels

Current treatments for Alzheimer’s disease (AD) attenuate the progression of symptoms and aim to improve the patient’s quality of life. Licensed medicines are mostly for oral administration and are limited by the difficulty in crossing the blood–brain barrier (BBB). Here in, the nasal route has been...

Descripción completa

Detalles Bibliográficos
Autores principales: Cunha, Sara, Forbes, Ben, Sousa Lobo, José Manuel, Silva, Ana Catarina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8256381/
https://www.ncbi.nlm.nih.gov/pubmed/34234432
http://dx.doi.org/10.2147/IJN.S305851

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8256381/
https://www.ncbi.nlm.nih.gov/pubmed/34234432
http://dx.doi.org/10.2147/IJN.S305851

Ejemplares similares